Observational studyNature communications2022
The DNA methylome of cervical cells can predict the presence of ovarian cancer.
Observational study in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05678426 (TirolGESUND), which is not on this map. Cited by 36 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
TirolGESUND: General Exercise, Smoking Undone, and Nutrition Diet
Who cites it
36 citing papers in PubMed, 1 synthesis or guideline pooled it, 55 citations in OpenAlex.
- Cervicovaginal specimen biomarkers for early detection of ovarian and endometrial cancer: A review.Cancer medicine · 2024Pooled it
- High-grade serous ovarian cancer is associated with increased TP53 mutation burden in uterine lavage.NPJ precision oncology · 2026Article
- Individualised progesterone receptor modulator prevention strategies for triple-negative breast cancer in BRCA1 pathogenic variant carriers.NPJ breast cancer · 2026Review
- The cervico-vaginal DNA methylation WID-qEC test: An epigenetic marker associated with ovarian cancer in the absence of endometrial and cervical cancer.International journal of cancer · 2026Article
- Somatic mutations in cervicovaginal samples: assessing their role in ovarian cancer detection and prognosis.Translational oncology · 2026Article
- Global epidemiology of ovarian cancer: patterns, trends, and risk factors.Cancer biology & medicine · 2026Review
- Prevention strategies for hereditary gynaecological cancer in Lynch syndrome.Familial cancer · 2026Review
- Article
- Development and validation of a prognostic model for efferocytosis-associated genes in cervical squamous cell carcinoma.Discover oncology · 2025Article
- Exploring potential methylation markers for ovarian cancer from cervical scraping samples.Human genomics · 2025Article
- Innovative qPCR Algorithm Using Platelet-Derived RNA for High-Specificity and Cost-Effective Ovarian Cancer Detection.Cancers · 2025Article
- Functionally enriched epigenetic clocks reveal tissue-specific discordant aging patterns in individuals with cancer.Communications medicine · 2025Article
- Systems epigenetic approach towards non-invasive breast cancer detection.Nature communications · 2025Article
- Epigenetic signatures in surrogate tissues are able to assess cancer risk and indicate the efficacy of preventive measures.Communications medicine · 2025Article
- Potential use of DNA methylation in cervical swabs for early ovarian cancer diagnosis.Journal of ovarian research · 2025Article
- Early Diagnosis of Ovarian Cancer: A Comprehensive Review of the Advances, Challenges, and Future Directions.Diagnostics (Basel, Switzerland) · 2025Review
- Using parenclitic networks on phaeochromocytoma and paraganglioma tumours provides novel insights on global DNA methylation.Scientific reports · 2024Article
- Technical and biological sources of unreliability of Infinium probes on Illumina methylation microarrays.Clinical epigenetics · 2024Article
- Exploring cross-tissue DNA methylation patterns: blood-brain CpGs as potential neurodegenerative disease biomarkers.Communications biology · 2024Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 6 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The vast majority of epithelial ovarian cancer arises from tissues that are embryologically derived from the Müllerian Duct. Here, we demonstrate that a DNA methylation signature in easy-to-access Müllerian Duct-derived cervical cells from women with and without ovarian cancer (i.e. referred to as the Women's risk IDentification for Ovarian Cancer index or WID-OC-index) is capable of identifying women with an ovarian cancer in the absence of tumour DNA with an AUC of 0.76 and women with an endometrial cancer with an AUC of 0.81. This and the observation that the cervical cell WID-OC-index mimics the epigenetic program of those cells at risk of becoming cancerous in BRCA1/2 germline mutation carriers (i.e. mammary epithelium, fallopian tube fimbriae, prostate) further suggest that the epigenetic misprogramming of cervical cells is an indicator for cancer predisposition. This concept has the potential to advance the field of risk-stratified cancer screening and prevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.